Examining the Autoimmune Disorder Rheumatoid Arthritis and the Genetic Determinants Contributing to its Genesis

Ranjbar, Ramesh; Shukripour, Ramin

doi:10.22034/ppmj.2026.2066237.1066

Examining the Autoimmune Disorder Rheumatoid Arthritis and the Genetic Determinants Contributing to its Genesis

Document Type : Original Article

Authors

Ramesh Ranjbar

Ramin Shukripour

Department of Biology, Faculty of Basic Sciences, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.

https://doi.org/10.22034/ppmj.2026.2066237.1066

Abstract

Rheumatoid arthritis (RA) is an irreversible systemic autoimmune disorder. The advancement of the illness results in joint deformity and associated functional impairment, which profoundly impacts the standard of life of those affected. This review offers an overview of rheumatoid arthritis (RA), including a broad introduction to the illness, its epidemiology, associated risks, and pathogenesis. It also emphasizes advancements in fundamental research and the many mechanisms of signaling and molecular processes, including genetic variables. Summary of previous studies: In recent decades, researchers have garnered more interest in rheumatoid arthritis. Aberrant signaling pathways in rheumatoid arthritis (RA) constitute a significant area of study for identifying and treating the condition, offering crucial insights for comprehending this complex illness and formulating relevant therapies. The etiology of rheumatoid arthritis is associated with several signaling pathways. Research has repeatedly examined the etiology of rheumatoid arthritis (RA), revealing that both environmental and genetic variables play significant roles in its onset. Additionally, several research indicates that the susceptibility and severity of rheumatoid arthritis (RA) may correlate with the HLA-DRB1 variant, which exhibits the most significant genetic relationship with RA.

Keywords

Rheumatoid arthritis

Signaling pathway

Autoimmune disease

Epidemiology

Subjects

pharmacogenomics

1. Alibeigi E, Dehkordi AA, Asadian M, Doosti A, Piri-Gharaghie T. Administration of Apis cerana cerana melittin gene-encapsulated pectin for breast cancer therapy: an investigation of a new anti-cancer agent. Cancer Nanotechnology. 2025 Dec;16(1):9.
2. Moosavi-Kohnehsari RS, Jafari-Sohi M, Piri-Gharaghie T, Tolou-Shikhzadeh-Yazdi S, Aghassizadeh-Sherbaf M, Hosseinzadeh R. A new vaccination approach for Salmonellosis employing a multi-epitope vaccine based on live microbial cell factory from Lactococcus lactis. Poultry Science. 2025 Feb 1;104(2):104789.
3. Ding, Q., et al., Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduction and Targeted Therapy, 2023. 8(1): p. 68.
4. Coutant, F. and P. Miossec, Evolving concepts of the pathogenesis of rheumatoid arthritis with focus on the early and late stages. Current opinion in rheumatology, 2020. 32(1): p. 57-63.
5. Kurkó, J., et al., Genetics of rheumatoid arthritis—a comprehensive review. Clinical reviews in allergy & immunology, 2013. 45: p. 170-179.
6. Figus, F.A., et al., Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmunity reviews, 2021. 20(4): p. 102776.
7. Pope, J.E., Management of fatigue in rheumatoid arthritis. RMD open, 2020. 6(1): p. e001084.
8. Majithia, V. and S.A. Geraci, Rheumatoid arthritis: diagnosis and management. The American journal of medicine, 2007. 120(11): p. 936-939.
9. Li, X. and Y. Su, Diagnosis and treatment of early rheumatoid arthritis. Zhonghua nei ke za zhi, 2020. 59(9): p. 724-727.
10.Radu, A.-F. and S.G. Bungau, Management of rheumatoid arthritis: an overview. Cells, 2021. 10(11): p. 2857.
11.Landré-Beauvais, A.J., The first description of rheumatoid arthritis. Unabridged text of the doctoral dissertation presented in 1800. Joint bone spine, 2001. 68(2): p. 130-143.
12.Otón, T. and L. Carmona, The epidemiology of established rheumatoid arthritis. Best Practice & Research Clinical Rheumatology, 2019. 33(5): p. 101477.
13.Wasserman, A., Rheumatoid arthritis: common questions about diagnosis and management. American family physician, 2018. 97(7): p. 455-462.
14.Almutairi, K., et al., The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatology international, 2021. 41(5): p. 863-877.
15.Bykerk, V.P. and E.M. Massarotti, The new ACR/EULAR classification criteria for RA: how are the new criteria performing in the clinic? Rheumatology, 2012. 51(suppl_6): p. vi10-vi15.
16.Mjaavatten, M.D. and V.P. Bykerk, Early rheumatoid arthritis: the performance of the 2010 ACR/EULAR criteria for diagnosing RA. Best practice & research Clinical rheumatology, 2013. 27(4): p. 451-466.
17.Firestein, G.S. and I.B. McInnes, Immunopathogenesis of rheumatoid arthritis. Immunity, 2017. 46(2): p. 183-196.
18.Turesson, C., et al., Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Annals of the rheumatic diseases, 2003. 62(8): p. 722.
19.Yu, H.-C. and M.-C. Lu, The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis. Tzu-Chi Medical Journal, 2019. 31(1): p. 5.
20.Essouma, M. and J.J.N. Noubiap, Is air pollution a risk factor for rheumatoid arthritis? Journal of Inflammation, 2015. 12: p. 1-7.
21.Alsaber, A., et al., Influence of ambient air pollution on rheumatoid arthritis disease activity score index. International journal of environmental research and public health, 2020. 17(2): p. 416.
22.Itoh, Y., Metalloproteinases in rheumatoid arthritis: potential therapeutic targets to improve current therapies. Progress in molecular biology and translational science, 2017. 148: p. 327-338.
23.Yasuda, T., Cartilage destruction by matrix degradation products. Modern rheumatology, 2006. 16: p. 197-205.
24.Geusens, P., The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Therapeutic advances in musculoskeletal disease, 2012. 4(4): p. 225-233.
25.Nasirian H, TarvijEslami S, Ghourchian H, Ebrahimi M, Piri-Gharaghie T, Ghajari G. Niosomes containing enciprazine hydrochloride have been shown to efficiently inhibit the proliferation and induce apoptosis in colorectal cancer cells. Advances in Cancer Biology-Metastasis. 2024 Dec 1;12:100128.
26.Kehlen, A., et al., Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clinical & Experimental Immunology, 2002. 127(3): p. 539-546.
27.Yap, H.-Y., et al., Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells, 2018. 7(10): p. 161.
28.Phull, A.-R., et al., Oxidative stress, consequences and ROS mediated cellular signaling in rheumatoid arthritis. Chemico-biological interactions, 2018. 281: p. 121-136.
29.Abbas, M. and M. Monireh, The role of reactive oxygen species in immunopathogenesis of rheumatoid arthritis. Iranian Journal of Allergy, Asthma and Immunology, 2008: p. 195-202.
30.Holers, V.M. and N.K. Banda, Complement in the initiation and evolution of rheumatoid arthritis. Frontiers in immunology, 2018. 9: p. 1057.
31.Kadura, S. and G. Raghu, Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. European Respiratory Review, 2021. 30(160).
32.Dai, Y., et al., Rheumatoid arthritis–associated interstitial lung disease: an overview of epidemiology, pathogenesis and management. Clinical rheumatology, 2021. 40: p. 1211-1220.
33.England, B.R. and D. Hershberger, Management issues in rheumatoid arthritis-associated interstitial lung disease. Current opinion in rheumatology, 2020. 32(3): p. 255.
34.Zagora, S.L., et al., Inflammatory eye and rheumatic disease. International journal of rheumatic diseases, 2019. 22(12): p. 2091-2095.
35.Promelle, V., V. Goeb, and J. Gueudry, Rheumatoid arthritis associated episcleritis and scleritis: an update on treatment perspectives. Journal of clinical medicine, 2021. 10(10): p. 2118.
36.Ouederni, M., H. Sassi, and M. Cheour, Multinodular scleritis in a patient with rheumatoid arthritis. Clinical Rheumatology, 2021. 40(10): p. 4359-4360.
37.Adami, G., et al., Association between environmental air pollution and rheumatoid arthritis flares. Rheumatology, 2021. 60(10): p. 4591-4597.
38.Song, G.G., S.-C. Bae, and Y.H. Lee, Association between vitamin D intake and the risk of rheumatoid arthritis: a meta-analysis. Clinical rheumatology, 2012. 31: p. 1733-1739.
39.Maeda, Y. and K. Takeda, Host–microbiota interactions in rheumatoid arthritis. Experimental & Molecular Medicine, 2019. 51(12): p. 1-6.
40.Wells, P.M., et al., ‘RA and the microbiome: do host genetic factors provide the link? Journal of Autoimmunity, 2019. 99: p. 104-115.
41.Li, M. and F. Wang, Role of intestinal microbiota on gut homeostasis and rheumatoid arthritis. Journal of immunology research, 2021. 2021.
42.Zhang, Y., et al., Overview of histone modification. Histone Mutations and Cancer, 2021: p. 1-16.
43.Araki, Y., et al., Altered gene expression profiles of histone lysine methyltransferases and demethylases in rheumatoid arthritis synovial fibroblasts. Clinical and Experimental Rheumatology, 2018. 36(2): p. 314-316.
44.Niederer, F., Inflammation and apoptosis in the synovium of patients with rheumatoid arthritis: the role of SIRT1 and microRNA-34a. 2012, ETH Zurich.
45.Göschl, L., et al., Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis. Journal of autoimmunity, 2020. 108: p. 102379.
46.Horiuchi, M., et al., Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. The Journal of rheumatology, 2009. 36(8): p. 1580-1589.
47.Chung, Y.-L., et al., A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Molecular Therapy, 2003. 8(5): p. 707-717.
48.Nishida, K., et al., Histone deacetylase inhibitor suppression of autoantibody‐mediated arthritis in mice via regulation of p16INK4a and p21WAF1/Cip1 expression. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 2004. 50(10): p. 3365-3376.
49.Tammen, S.A., S. Friso, and S.-W. Choi, Epigenetics: the link between nature and nurture. Molecular aspects of medicine, 2013. 34(4): p. 753-764.
50.Corvetta, A., et al., 5-Methylcytosine content of DNA in blood, synovial mononuclear cells and synovial tissue from patients affected by autoimmune rheumatic diseases. Journal of Chromatography B: Biomedical Sciences and Applications, 1991. 566(2): p. 481-491.
51.Doody, K.M., N. Bottini, and G.S. Firestein, Epigenetic alterations in rheumatoid arthritis fibroblast-like synoviocytes. Epigenomics, 2017. 9(4): p. 479-492.
52.Karouzakis, E., et al., DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 2009. 60(12): p. 3613-3622.
53.Cai, Y., et al., A brief review on the mechanisms of miRNA regulation. Genomics, proteomics & bioinformatics, 2009. 7(4): p. 147-154.
54.Saliminejad, K., et al., An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. Journal of cellular physiology, 2019. 234(5): p. 5451-5465.
55.Michlewski, G. and J.F. Cáceres, Post-transcriptional control of miRNA biogenesis. Rna, 2019. 25(1): p. 1-16.
56.Jonas, S. and E. Izaurralde, Towards a molecular understanding of microRNA-mediated gene silencing. Nature reviews genetics, 2015. 16(7): p. 421-433.
57.Guo, Q., et al., Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone research, 2018. 6(1): p. 15.
58.Singh, J.A., et al., 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & rheumatology, 2016. 68(1): p. 1-26.
59.Moura, M.D.G., et al., Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review protocol. Medicine, 2018. 97(41).
60.Yamaoka, K., Tofacitinib for the treatment of rheumatoid arthritis: an update. Expert Review of Clinical Immunology, 2019. 15(6): p. 577-588.
61.Weckx, L.L.M., et al., Efficacy of celecoxib in treating symptoms of viral pharyngitis: a double-blind, randomized study of celecoxib versus diclofenac. Journal of international medical research, 2002. 30(2): p. 185-194.
62.Buttgereit, F. and A. Gibofsky, Delayed-release prednisone–a new approach to an old therapy. Expert opinion on pharmacotherapy, 2013. 14(8): p. 1097-1106.
63.Henness, S. and L.P. Yang, Modified-release prednisone: in patients with rheumatoid arthritis. Drugs, 2013. 73: p. 2067-2076.
64.Plosker, G.L. and K.F. Croom, Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs, 2005. 65: p. 1825-1849.
65.Dale, J., et al., Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nature clinical practice rheumatology, 2007. 3(8): p. 450-458.
66.Zhao, C., et al., Sulfasalazine promotes ferroptosis through AKT-ERK1/2 and P53-SLC7A11 in rheumatoid arthritis. Inflammopharmacology, 2024. 32(2): p. 1277-1294.
67.Zhou, J., et al., ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica, 2020. 105(9): p. 2286.
68.Nazir, A.M., et al., Evaluating the use of hydroxychloroquine in treating patients with rheumatoid arthritis. Cureus, 2021. 13(11).
69.Gravallese, E.M. and G.S. Firestein, Rheumatoid arthritis—common origins, divergent mechanisms. New England Journal of Medicine, 2023. 388(6): p. 529-542.
70.Zhao, Z., et al., Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomedicine & Pharmacotherapy, 2022. 150: p. 113074.
71.Kondo, N., T. Kuroda, and D. Kobayashi, Cytokine networks in the pathogenesis of rheumatoid arthritis. International journal of molecular sciences, 2021. 22(20): p. 10922.
72.Yip, R.M.L. and C.W. Yim, Role of interleukin 6 inhibitors in the management of rheumatoid arthritis. JCR: Journal of Clinical Rheumatology, 2021. 27(8): p. e516-e524.
73.Towns, M., J. Bathon, and H.R. IL, Inhibition of Interleukin-1 as a Strategy for the Treatment of Rheumatoid Arthritis. The Johns Hopkins arthritis center, http://www. hopkinsarthritis. org/arthritis-info/rheumatoid-arthritis/il1. html, last updated, 2009.
74.Ghajari G, Moosavi R. Evaluation of the effects of diazinon toxin on some reproductive parameters in male rats. Personalized Medicine Journal. 2022 Jun 20;7(25):30-5.
75.Piri-Gharaghie T, Ghajari G, Rezaeizadeh G, Adil M, Mahdi MH. A novel vaccine strategy against brucellosis using Brucella abortus multi-epitope OMPs vaccine based on Lactococcus lactis live bacterial vectors. International Immunopharmacology. 2024 Jun 15;134:112204.